Sorafenib a Possible Option for Medullary Thyroid Carcinoma?

Sorafenib a Possible Option for Medullary Thyroid Carcinoma?

Sorafenib (Nexavar, Bayer/Onyx) may be a good alternative for the treatment of advanced medullary thyroid cancer (MTC) when two agents approved for this carcinoma, vandetanib (Calpresa, AstraZeneca) and cabozantinib (Cometriq, Exelixis), are not …

12
Like
Save

Comments

Comments are disabled for this post.